FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993213958> ?p ?o ?g. }

• W1993213958 endingPage "980" @default.
• W1993213958 startingPage "973" @default.
• W1993213958 abstract "3-AP is a ribonucleotide reductase inhibitor and has been postulated to act synergistically with other chemotherapeutic agents. This study was conducted to determine the toxicity and antitumor activity of 3-AP with irinotecan. Correlative studies included pharmacokinetics and the effects of ABCB1 and UGT1A1 polymorphisms. The treatment plan consisted of irinotecan on day 1 with 3-AP on days 1–3 of a 21-day cycle. Starting dose was irinotecan 150 mg/m2 and 3-AP 85 mg/m2 per day. Polymorphisms of ABCB1 were evaluated by pyrosequencing. Drug concentrations were determined by HPLC. Twenty-three patients were enrolled, 10 men and 13 women. Tumor types included seven patients with pancreatic cancer, four with lung cancer, two with cholangiocarcinoma, two with mesothelioma, two with ovarian cancer, and six with other malignancies. Two patients experienced dose-limiting toxicity (DLT) at dose level 1, requiring amendment of the dose-escalation scheme. Maximal tolerated dose (MTD) was determined to be 3-AP 60 mg/m2 per day and irinotecan 200 mg/m2. DLTs consisted of hypoxia, leukopenia, fatigue, infection, thrombocytopenia, dehydration, and ALT elevation. One partial response in a patient with refractory non-small cell lung cancer was seen. Genotyping suggests that patients with wild-type ABCB1 have a higher rate of grade 3 or 4 toxicity than those with ABCB1 mutations. The MTD for this combination was 3-AP 60 mg/m2 per day on days 1–3 and irinotecan 200 mg/m2 on day 1 every 21 days. Antitumor activity in a patient with refractory non-small cell lung cancer was noted at level 1." @default.
• W1993213958 created "2016-06-24" @default.
• W1993213958 creator A5015092618 @default.
• W1993213958 creator A5016348831 @default.
• W1993213958 creator A5017798288 @default.
• W1993213958 creator A5037903114 @default.
• W1993213958 creator A5058977584 @default.
• W1993213958 creator A5061697254 @default.
• W1993213958 creator A5073864381 @default.
• W1993213958 creator A5080736692 @default.
• W1993213958 creator A5087847418 @default.
• W1993213958 creator A5091511322 @default.
• W1993213958 date "2010-02-02" @default.
• W1993213958 modified "2023-10-16" @default.
• W1993213958 title "The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors" @default.
• W1993213958 cites W1977450976 @default.
• W1993213958 cites W1977482169 @default.
• W1993213958 cites W1982847073 @default.
• W1993213958 cites W1984353977 @default.
• W1993213958 cites W1986778880 @default.
• W1993213958 cites W1991205228 @default.
• W1993213958 cites W2019227458 @default.
• W1993213958 cites W2021034741 @default.
• W1993213958 cites W2035105453 @default.
• W1993213958 cites W2073683299 @default.
• W1993213958 cites W2077500782 @default.
• W1993213958 cites W2083315452 @default.
• W1993213958 cites W2096122707 @default.
• W1993213958 cites W2103041841 @default.
• W1993213958 cites W2111016379 @default.
• W1993213958 cites W2118226539 @default.
• W1993213958 cites W2130906098 @default.
• W1993213958 cites W2139248078 @default.
• W1993213958 cites W2140496330 @default.
• W1993213958 cites W2164529446 @default.
• W1993213958 doi "https://doi.org/10.1007/s00280-010-1250-z" @default.
• W1993213958 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2921466" @default.
• W1993213958 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20127092" @default.
• W1993213958 hasPublicationYear "2010" @default.
• W1993213958 type Work @default.
• W1993213958 sameAs 1993213958 @default.
• W1993213958 citedByCount "17" @default.
• W1993213958 countsByYear W19932139582012 @default.
• W1993213958 countsByYear W19932139582013 @default.
• W1993213958 countsByYear W19932139582014 @default.
• W1993213958 countsByYear W19932139582019 @default.
• W1993213958 countsByYear W19932139582020 @default.
• W1993213958 countsByYear W19932139582021 @default.
• W1993213958 countsByYear W19932139582022 @default.
• W1993213958 countsByYear W19932139582023 @default.
• W1993213958 crossrefType "journal-article" @default.
• W1993213958 hasAuthorship W1993213958A5015092618 @default.
• W1993213958 hasAuthorship W1993213958A5016348831 @default.
• W1993213958 hasAuthorship W1993213958A5017798288 @default.
• W1993213958 hasAuthorship W1993213958A5037903114 @default.
• W1993213958 hasAuthorship W1993213958A5058977584 @default.
• W1993213958 hasAuthorship W1993213958A5061697254 @default.
• W1993213958 hasAuthorship W1993213958A5073864381 @default.
• W1993213958 hasAuthorship W1993213958A5080736692 @default.
• W1993213958 hasAuthorship W1993213958A5087847418 @default.
• W1993213958 hasAuthorship W1993213958A5091511322 @default.
• W1993213958 hasBestOaLocation W19932139582 @default.
• W1993213958 hasConcept C112705442 @default.
• W1993213958 hasConcept C121608353 @default.
• W1993213958 hasConcept C126322002 @default.
• W1993213958 hasConcept C142424586 @default.
• W1993213958 hasConcept C2776256026 @default.
• W1993213958 hasConcept C2780259306 @default.
• W1993213958 hasConcept C2780873365 @default.
• W1993213958 hasConcept C29730261 @default.
• W1993213958 hasConcept C526805850 @default.
• W1993213958 hasConcept C71924100 @default.
• W1993213958 hasConcept C86803240 @default.
• W1993213958 hasConcept C87355193 @default.
• W1993213958 hasConcept C90924648 @default.
• W1993213958 hasConcept C98274493 @default.
• W1993213958 hasConceptScore W1993213958C112705442 @default.
• W1993213958 hasConceptScore W1993213958C121608353 @default.
• W1993213958 hasConceptScore W1993213958C126322002 @default.
• W1993213958 hasConceptScore W1993213958C142424586 @default.
• W1993213958 hasConceptScore W1993213958C2776256026 @default.
• W1993213958 hasConceptScore W1993213958C2780259306 @default.
• W1993213958 hasConceptScore W1993213958C2780873365 @default.
• W1993213958 hasConceptScore W1993213958C29730261 @default.
• W1993213958 hasConceptScore W1993213958C526805850 @default.
• W1993213958 hasConceptScore W1993213958C71924100 @default.
• W1993213958 hasConceptScore W1993213958C86803240 @default.
• W1993213958 hasConceptScore W1993213958C87355193 @default.
• W1993213958 hasConceptScore W1993213958C90924648 @default.
• W1993213958 hasConceptScore W1993213958C98274493 @default.
• W1993213958 hasIssue "5" @default.
• W1993213958 hasLocation W19932139581 @default.
• W1993213958 hasLocation W19932139582 @default.
• W1993213958 hasLocation W19932139583 @default.
• W1993213958 hasLocation W19932139584 @default.
• W1993213958 hasOpenAccess W1993213958 @default.
• W1993213958 hasPrimaryLocation W19932139581 @default.
• W1993213958 hasRelatedWork W1928747779 @default.

• next